Tikun Europe and Lavipharm enter into a strategic alliance – Through the collaboration between the two companies, the new Tikun products, expected to be launched in 2023, will be distributed in Greece by Lavipharm

Tikun Europe and Lavipharm enter into a strategic alliance – Through the collaboration between the two companies, the new Tikun products, expected to be launched in 2023, will be distributed in Greece by Lavipharm

 Athens, 15 November 2022: Tikun Europe, the leading pharmaceutical company in research, development and production of medical cannabis products in Greece, and the Greek pharmaceutical group Lavipharm are entering into a strategic partnership for the distribution of Tikun’s new products, which are anticipated to be launched in the Greek market in 2023.

Tikun’s new product lines concern both the finished medical cannabis products that will be produced exclusively at its facility in Greece, and the new specialized line of cannabidiol (CBD) food supplements to be produced at a certified plant in France. As part of the agreement, Lavipharm will assume the commercial distribution of Tikun’s products in the Greek market. The duration of the contract is 5 years, with an option to further renew.

The market for medical cannabis in Europe is growing rapidly, reflecting the need of both the medical community and patients. In the Greek market, the agreement with Tikun Europe further strengthens Lavipharm’s portfolio in the therapeutic categories of focus, such as Oncology, Chronic Pain and the Central Nervous System.

Mr. Nikos Beis, CEO Tikun Europe, noted that “The Tikun Europe team is very pleased to welcome this strategic alliance with Lavipharm, a historic and innovative Greek pharmaceutical group, representing another significant move for us. The two companies are joining forces – starting with production at Tikun’s plant and then with commercialisation through the Lavipharm channels – to give Greek patients access to medication that they have not had until today. This new agreement serves our strategic decision to create alliances with major pharmaceutical partners, Lavipharm and Pharmaserve Hellas, with the aim to make available high quality medical cannabis products that are effective in supporting the treatment of patients with severe conditions, as well as a new line of CBD food supplements for improving consumers overall well-being.”

Mr. Telemaque Lavidas, Executive Board Member of Lavipharm, commented “We are excited about the strategic alliance between Lavipharm and Tikun Europe, a company with a state-of-the-art pharmaceutical plant in Greece that meets the strictest standards in the world. The aim of our partnership is to give patients access – which they have not had to date – to medical cannabis treatments for a wide range of conditions, and to improve consumers’ quality of life with CBD food supplements. At the same time, we are expanding our portfolio in the categories where we already operate with trusted, effective and safe pharmaceuticals, remaining faithful to our strategic focus.” Commenting further, Mr. Lavidas added that “Lavipharm’s new agreement and the recent collaboration between Tikun Europe and a respectable counterpart such as Pharmaserve Hellas points to the need for major companies with a significant footprint in the Greek pharmaceutical market to ensure that healthcare professionals (doctors and pharmacists) have access to scientifically documented information for the benefit of patients.”


Regarding TIKUN

TIKUN is a pioneering company in the research, development, and production of medicinal cannabis products worldwide. Defining the market of medicinal cannabis in 2005, it began its activity in Israel and in the course of time expanded with production units in the USA, Canada, Australia, Asia (Israel) and Europe (based in Greece). With more than 15 years of clinical and laboratory studies and an extensive database of tens of thousands of patients worldwide, TIKUN’s innovative pharmaceutical formulations are based on cannabis strains that have been awarded worldwide.Its medications offer support for serious conditions, such as Parkinson’s disease, Crohn’s disease, Autism, multiple sclerosis, epilepsy, side effects from chemotherapy, neuropathic pain, etc.

About TIKUN Europe

TIKUN’s presence in Europe began in Greece, taking advantage of the country’s potential to develop into an international center for the production of medical cannabis, with most of the production intended for exports to Europe.

With a total investment of €40m, in a 56,000m2 area in Corinth, TIKUN Europe has created the largest, for this sector, production unit in Europe, with a vertically integrated production process and an R&D department, in state-of-the-art facilities and with hi-tech equipment.

TIKUN Europe’s activity is fully aligned with the Greek legislation provisions for the cultivation and processing of cannabis, aiming at the creation of pharmaceutical formulations that will be produced in a GMP environment and by applying strict control standards and procedures which ensure high quality and safety.

The company utilizes TIKUN’s know-how, while having direct access to its large patient database. TIKUN’s pharmaceutical formulations have effectiveness which has been verified following clinical studies and Real Clinical Practice Data (RWD).

In addition, TIKUN Europe has been on the market since the beginning of 2022 with the TIKUN CBD product line produced in a certified factory in France, based on innovative formulas developed by its R&D division. The Tikun CBD food supplement range includes 5 products and targets everyday discomforts while also benefitting the whole body by providing holistic, natural balance.

 About Lavipharm

Lavipharm has been active in the pharmaceutical field since 1911, always aiming to support the vital work of doctors and pharmacists by providing reliable therapy options. Its portfolio includes innovative and effective pharmaceutical products that meet patients’ daily needs. With over a century of history, it is today an integrated pharmaceutical group engaged in research, development, production, marketing and distribution in Greece, with strong international activity. Since 1995, the company has been listed on the Athens Stock Exchange (ASE: LAVI).

Media info

V+O Communication, Nasia Bourni – Tel. Contact 210 72 49 000 / +30 6936775484 – Email nb@vando.gr

Lavipharm, Katerina Fragioudakis – Tel.+30 210 6691 106 – Email: communcations@lavipharm.com